![Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche;
PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer](https://european-biotechnology.com/wp-content/uploads/2024/04/2016_11-15_RocheCIT-180x180.jpg "2016_11-15_RocheCIT.jpg")
Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.
Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.
Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.
Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.
Oxford-based immuno-oncology play Adaptimmune has been obliged by the FDA to alter the trial design of a Phase I/II study in patients with MRCLS. A partial clinical hold was lifted now.
Belgian and German researchers have presented a new imaging tool that can track immune cells invading the brain in the initial stages of multiple sclerosis (MS).
Compassionate use is a treatment option that allows the use of an unauthorised medicine.
PromoKine’s new Cell Proliferation Assays are fast and sensitive and EdU-based.
Despite declining numbers of IPOs, financing rounds and licensing deals, the European biotech sector presented itself optimistic and self-confident during BIO-Europe in Cologne. The three-days partnering event again see a record number of participants.
Cologne-based biotech Ayoxxa Biosystems GmbH announces that Rodney Turner has assumed duties as the interim CEO. Prior CEO Andreas Schmidt has stepped down.